View Financial HealthSOHM 配当と自社株買い配当金 基準チェック /06SOHM配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jul 03Sohm, Inc. Appoints Ravi Kapoor as an Independent DirectorSOHM, Inc. announced the appointment of Mr. Ravi Kapoor as an Independent Director. With over three decades of extensive experience in corporate law, mergers and acquisitions (M&A), and financial management, Mr. Kapoor brings a wealth of expertise to the SOHM Board that will enhance the company's strategic vision and governance framework. Mr. Kapoor is the proprietor of Ravi Kapoor &Associates and a partner at Yan Advisory Services LLP and Amity Consultants LLP. He is a registered Insolvency Professional with the Insolvency &Bankruptcy Board of India, demonstrating his commitment to upholding the highest standards in corporate governance. He holds multiple qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, which have equipped him with a thorough understanding of the complexities of corporate operations. His professional journey spans various esteemed institutions and includes primary roles as a Company Secretary with notable companies. Throughout his career, Mr. Kapoor has served on the boards of several prestigious organizations, including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise), where his contributions have been pivotal in driving growth and innovation.お知らせ • Jun 13SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-Cell Immunotherapy from a Healthy Human DonorSOHM, Inc. announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T-Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. Dr. Aguilar, further stated that, CAR T-cell therapy is a form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells. The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options. The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer. In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses. On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells. Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers.お知らせ • May 24Sohm, Inc. Targets Revolutionary New Abbie Genome Editing Kits for Third Quarter, 2024SOHM, Inc. announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This technology has the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The impact of ABBIE on genome editing cannot be overstated. By providing researchers with a powerful tool for targeted integration of foreign DNA, ABBIE has the potential to revolutionize the field of genetic engineering and open up new possibilities for the treatment of genetic diseases, the development of novel therapies, and the advancement of scientific research. The increased efficiency of safe genetic insertions with ABBIE will decrease time to obtain successful edits and the costs associated with lost time and additional reagents. The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in third quarter. This has been possible due to committed, consistent and focused approach by lead scientists at UACI in Tucson, AZ. The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development.お知らせ • Nov 16SOHM, Inc. Launches Suite of 13 New SOHM Nutrients' Brand ChewablesSOHM, Inc. announced SOHM OTC Self-care launches a suite of 13 new SOHM Nutrients' Brand Chewables. SOHM OTC Self -care business unit is launching its suite of 13 new SohM Nutrients' Brand CheWables into the global vitamin gummies market. The global vitamins market is valued at $6.84 billion in 2022 and is expected to reach $18.76 billion by 2031 with a CAGR of 12.06% between 2023-2031. The suite of these 13 SOHM Nutrients’ Brand Chewables will be offering consumers these key features: Bone health, skin health, immune boost, mineral replenishment, and sleep aid; Convenience of individually wrapped single serving (pocket friendly); Chewables (no water required); Taste (mango, strawberry, pineapple, toffee). These SOHM Nutrients’ Brand Chewables also boast the same sought-after ingredients and labels as the leading vitamin gummies on Amazon.com: Turmeric, folic acid, multi-vitamins, multi-minerals; Nuts free; Gluten free; Gelatin free; Vegan; Soy free.お知らせ • Aug 25SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical AdvisorSOHM, Inc. announced the appointment of Dr. Krishna Bhat, MD. Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor. Baron Night, SOHM president and CEO, said Dr. Bhathas a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which states: "In recognition of your commitment to excellence in the field of Cardiovascular Care through your leadership as an outstanding physician, researcher, and educator." Dr. Bhat also received the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada.お知らせ • Aug 09SOHM, Inc. Appoints Dr. David Aguilar, Ph.D. as A Chief Operating OfficerSOHM, Inc. announce the appointment of Dr. David Aguliar, Ph.D. as Chief Operating Officer, effective immediately. Mr. Baron Night, CEO and President is please to share that, Dr. David Aguliar has a total of 22 years of experience in pharmaceutical industry coupled with multiple research and publications. He has an extensive background in significant CMC and Quality Assurance experience in preclinical and IND filings of allogeneic cell-based therapies. A deep understanding of regulatory and clinical pathways coupled with extensive scientific and technical background offers a unique perspective in developing assets from concept to clinic. His extensive academic and corporate experience in the field of pharmaceuticals, biopharmaceuticals and Gene Editing tools research etc. is a phenomenon. With his appointment as a COO, the company shall benefit tremendously for its vision and goals. Dr. Aguilar's Exceptional track record of following leadership will enhance the company's ability to achieve the goals and vision more quickly. His skills include but not limited to; Superior project management skills, Resourceful and analytical with exceptional communication skills, Understanding of all facets of business, Outstanding public speaking and interpersonal skills, Knowledge of AI tools and implementation in the current business infrastructure, Aptitude in problem-solving and decision-making, Understanding of analytics and performance metrics.決済の安定と成長配当データの取得安定した配当: SHMNの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: SHMNの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場SOHM 配当利回り対市場SHMN 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SHMN)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Pharmaceuticals)2.1%アナリスト予想 (SHMN) (最長3年)n/a注目すべき配当: SHMNは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: SHMNは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: SHMNの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: SHMNが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 16:42終値2026/05/22 00:00収益2012/12/31年間収益2012/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SOHM, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 03Sohm, Inc. Appoints Ravi Kapoor as an Independent DirectorSOHM, Inc. announced the appointment of Mr. Ravi Kapoor as an Independent Director. With over three decades of extensive experience in corporate law, mergers and acquisitions (M&A), and financial management, Mr. Kapoor brings a wealth of expertise to the SOHM Board that will enhance the company's strategic vision and governance framework. Mr. Kapoor is the proprietor of Ravi Kapoor &Associates and a partner at Yan Advisory Services LLP and Amity Consultants LLP. He is a registered Insolvency Professional with the Insolvency &Bankruptcy Board of India, demonstrating his commitment to upholding the highest standards in corporate governance. He holds multiple qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, which have equipped him with a thorough understanding of the complexities of corporate operations. His professional journey spans various esteemed institutions and includes primary roles as a Company Secretary with notable companies. Throughout his career, Mr. Kapoor has served on the boards of several prestigious organizations, including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise), where his contributions have been pivotal in driving growth and innovation.
お知らせ • Jun 13SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-Cell Immunotherapy from a Healthy Human DonorSOHM, Inc. announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T-Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. Dr. Aguilar, further stated that, CAR T-cell therapy is a form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells. The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options. The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer. In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses. On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells. Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers.
お知らせ • May 24Sohm, Inc. Targets Revolutionary New Abbie Genome Editing Kits for Third Quarter, 2024SOHM, Inc. announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This technology has the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The impact of ABBIE on genome editing cannot be overstated. By providing researchers with a powerful tool for targeted integration of foreign DNA, ABBIE has the potential to revolutionize the field of genetic engineering and open up new possibilities for the treatment of genetic diseases, the development of novel therapies, and the advancement of scientific research. The increased efficiency of safe genetic insertions with ABBIE will decrease time to obtain successful edits and the costs associated with lost time and additional reagents. The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in third quarter. This has been possible due to committed, consistent and focused approach by lead scientists at UACI in Tucson, AZ. The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development.
お知らせ • Nov 16SOHM, Inc. Launches Suite of 13 New SOHM Nutrients' Brand ChewablesSOHM, Inc. announced SOHM OTC Self-care launches a suite of 13 new SOHM Nutrients' Brand Chewables. SOHM OTC Self -care business unit is launching its suite of 13 new SohM Nutrients' Brand CheWables into the global vitamin gummies market. The global vitamins market is valued at $6.84 billion in 2022 and is expected to reach $18.76 billion by 2031 with a CAGR of 12.06% between 2023-2031. The suite of these 13 SOHM Nutrients’ Brand Chewables will be offering consumers these key features: Bone health, skin health, immune boost, mineral replenishment, and sleep aid; Convenience of individually wrapped single serving (pocket friendly); Chewables (no water required); Taste (mango, strawberry, pineapple, toffee). These SOHM Nutrients’ Brand Chewables also boast the same sought-after ingredients and labels as the leading vitamin gummies on Amazon.com: Turmeric, folic acid, multi-vitamins, multi-minerals; Nuts free; Gluten free; Gelatin free; Vegan; Soy free.
お知らせ • Aug 25SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical AdvisorSOHM, Inc. announced the appointment of Dr. Krishna Bhat, MD. Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor. Baron Night, SOHM president and CEO, said Dr. Bhathas a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which states: "In recognition of your commitment to excellence in the field of Cardiovascular Care through your leadership as an outstanding physician, researcher, and educator." Dr. Bhat also received the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada.
お知らせ • Aug 09SOHM, Inc. Appoints Dr. David Aguilar, Ph.D. as A Chief Operating OfficerSOHM, Inc. announce the appointment of Dr. David Aguliar, Ph.D. as Chief Operating Officer, effective immediately. Mr. Baron Night, CEO and President is please to share that, Dr. David Aguliar has a total of 22 years of experience in pharmaceutical industry coupled with multiple research and publications. He has an extensive background in significant CMC and Quality Assurance experience in preclinical and IND filings of allogeneic cell-based therapies. A deep understanding of regulatory and clinical pathways coupled with extensive scientific and technical background offers a unique perspective in developing assets from concept to clinic. His extensive academic and corporate experience in the field of pharmaceuticals, biopharmaceuticals and Gene Editing tools research etc. is a phenomenon. With his appointment as a COO, the company shall benefit tremendously for its vision and goals. Dr. Aguilar's Exceptional track record of following leadership will enhance the company's ability to achieve the goals and vision more quickly. His skills include but not limited to; Superior project management skills, Resourceful and analytical with exceptional communication skills, Understanding of all facets of business, Outstanding public speaking and interpersonal skills, Knowledge of AI tools and implementation in the current business infrastructure, Aptitude in problem-solving and decision-making, Understanding of analytics and performance metrics.